Xencor, Inc. (NASDAQ:XNCR) Given Consensus Rating of “Buy” by Analysts

Xencor, Inc. (NASDAQ:XNCR) has been given an average rating of “Buy” by the eight ratings firms that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $35.75.

A number of research firms have issued reports on XNCR. BMO Capital Markets reiterated an “outperform” rating and issued a $34.00 price objective (up previously from $32.00) on shares of Xencor in a report on Friday, November 8th. Wedbush reissued an “outperform” rating and set a $38.00 price target on shares of Xencor in a research report on Thursday, November 7th. JPMorgan Chase & Co. upped their price objective on shares of Xencor from $27.00 to $28.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Finally, Royal Bank of Canada raised their target price on shares of Xencor from $31.00 to $34.00 and gave the company an “outperform” rating in a research note on Thursday, September 26th.

Xencor Trading Down 2.9 %

Shares of XNCR opened at $25.30 on Wednesday. Xencor has a 1-year low of $15.31 and a 1-year high of $26.84. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 0.01. The firm’s 50-day moving average price is $21.57 and its 200-day moving average price is $20.39. The firm has a market capitalization of $1.77 billion, a price-to-earnings ratio of -7.91 and a beta of 0.66.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, beating the consensus estimate of ($0.98) by $0.27. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The business had revenue of $10.70 million for the quarter, compared to analysts’ expectations of $14.59 million. During the same period in the previous year, the firm posted ($0.40) EPS. The business’s revenue was down 81.9% on a year-over-year basis. Sell-side analysts anticipate that Xencor will post -3.71 EPS for the current year.

Insider Activity at Xencor

In other Xencor news, CEO Bassil I. Dahiyat sold 3,366 shares of the stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $24.02, for a total transaction of $80,851.32. Following the sale, the chief executive officer now directly owns 352,615 shares in the company, valued at approximately $8,469,812.30. This trade represents a 0.95 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP John R. Desjarlais sold 68,684 shares of the business’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $23.48, for a total value of $1,612,700.32. Following the completion of the transaction, the vice president now owns 200,104 shares of the company’s stock, valued at $4,698,441.92. This represents a 25.55 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 121,328 shares of company stock valued at $2,879,673 over the last 90 days. Corporate insiders own 5.23% of the company’s stock.

Institutional Trading of Xencor

A number of institutional investors have recently made changes to their positions in XNCR. Quarry LP purchased a new stake in Xencor in the second quarter worth approximately $36,000. KBC Group NV boosted its stake in shares of Xencor by 63.5% in the 3rd quarter. KBC Group NV now owns 3,123 shares of the biopharmaceutical company’s stock worth $63,000 after buying an additional 1,213 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of Xencor in the second quarter worth $154,000. XTX Topco Ltd purchased a new stake in Xencor during the second quarter valued at $196,000. Finally, Rockefeller Capital Management L.P. bought a new position in Xencor in the third quarter valued at about $205,000.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.